Abstract:The Wnt/β-catenin pathway is constitutively active and promotes multiple tumor processes, including breast cancer metastasis. However, the underlying mechanism by which the Wnt/β-catenin pathway is constitutively activated in breast cancer metastasis remains unclear. Inhibition of Wnt antagonists is important for Wnt/β-catenin signaling activation, and post-transcriptional regulation of these antagonists by microRNAs (miRNAs) might be a possible mechanism underlying signaling activation. Regulation of nuclear pre-mRNA domain-containing 1A (RPRD1A) is a known inhibitor of cell growth and Wnt/β-catenin signaling activity, but the function and regulatory mechanism of RPRD1A in breast cancer have not been clarified. The aim of this study was to understand how regulators of the Wnt/β-catenin pathway may play a role in the metastasis of this cancer. Methods: RPRD1A expression and its association with multiple clinicopathological characteristics was analyzed immunohistochemically in human breast cancer specimens. miR-454-3p expression was analyzed using real-time PCR. RPRD1A or miR-454-3p knockdown and overexpression were used to determine the underlying mechanism of their functions in breast cancer cells. Xenografted tumor model, 3D invasive culture, cell migration and invasion assays and sphere formation assay were used to determine the biofunction of RPRD1A and miR-454-3p in breast cancer. Electrophoretic mobility shift assay (EMSA), luciferase reporter assay, and RNA immunoprecipitation (RIP) were performed to study the regulation and underlying mechanisms of RPRD1A and miR-454-3p expression and their correlation with the Wnt/β-catenin pathway in breast cancer. Results: The Wnt/β-catenin signaling antagonist RPRD1A was downregulated and its upstream regulator miR-454-3p was amplified and overexpressed in metastatic breast cancer, and both were correlated with overall and relapse-free survival in breast cancer patients. The suppression by miR-454-3p on RPRD1A was found to activate Wnt/β-catenin signaling, thereby promoting metastasis. Simultaneously, three other negative regulators of the Wnt/β-catenin pathway, namely, AXIN2, dickkopf WNT signaling pathway inhibitor (DKK) 3 and secreted frizzled related protein (SFRP) 1, were also found to be targets of miR-454-3p and were involved in the signaling activation. miR-454-3p was found to be involved in early metastatic processes and to promote the stemness of breast cancer cells and early relapse under both in vitro and in vivo conditions. Conclusions: The findings indicate that miR-454-3p-mediated suppression of Wnt/β-catenin antagonist RPRD1A, as well as AXIN2, DKK3 and SFRP1, sustains the constitutive activation of Wnt/β-catenin signaling; thus, miR-454-3p and RPRD1A might be potential diagnostic and therapeutic targets for breast cancer metastasis.

C5aR Deficiency Attenuates the Breast Cancer Development Via the P38/p21 Axis

Paper C5ar Deficiency Attenuates The Breast Cancer Development Via The P38/P21 Axis

Blockade of C5a Receptor Unleashes Tumor-Associated Macrophage Antitumor Response and Enhances CXCL9-dependent CD8+ T Cell Activity

C5aR1 is a Master Regulator in Colorectal Tumorigenesis Via Immune Modulation

Opposing roles for complement component C5a in tumor progression and the tumor microenvironment.

C3a-C3aR signaling promotes breast cancer lung metastasis via modulating carcinoma associated fibroblasts

P38 Mapk Inhibits Breast Cancer Metastasis Through Regulation Of Stromal Expansion

Blocking C5aR Signaling Promotes the Anti-Tumor Efficacy of PD-1/PD-L1 Blockade

Cullin-5 deficiency orchestrates the tumor microenvironment to promote mammary tumor development through CREB1-CCL2 signaling

Tip30/Cc3 Expression in Breast Carcinoma: Relation to Metastasis, Clinicopathologic Parameters, and P53 Expression

MiR-454-3p-Mediated Wnt/β-catenin Signaling Antagonists Suppression Promotes Breast Cancer Metastasis

CCL28 Promotes Breast Cancer Growth and Metastasis Through MAPK-mediated Cellular Anti-Apoptosis and Pro-Metastasis

C5aR Correlated with the Dissemination Capacity of Circulating Tumor Cells in Hepatocellular Carcinoma by Targeting INHBA-p-smad2/3-EMT/MMPs Axis.

Host-derived CCL5 is Critical for Mammary Tumor Growth and Metastasis (50.30)

A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells

TNFRSF9 Suppressed the Progression of Breast Cancer via the p38MAPK/PAX6 Signaling Pathway

Overexpression of complement C5a indicates poor survival and therapeutic response in metastatic renal cell carcinoma

CCL5-deficiency Enhances Intratumoral Infiltration of CD8(+) T Cells in Colorectal Cancer

Cancer‐associated Fibroblasts Promote PD‐L1 Expression in Mice Cancer Cells Via Secreting CXCL5

The adhesion-GPCR ADGRF5 fuels breast cancer progression by suppressing the MMP8-mediated antitumorigenic effects

An Integrated Analysis of C5AR2 Related to Malignant Properties and Immune Infiltration of Breast Cancer